



## Recent Advances in Cancer Immunology and Immunotherapy

Guest Editors:

**Dr. Chan-Yen Kuo**

**Dr. Chou-Chin Lan**

**Dr. Po-Chun Hsieh**

**Dr. Guan-Ting Liu**

Deadline for manuscript  
submissions:

**closed (30 September 2022)**

### Message from the Guest Editors

Cancer immunotherapy has revolutionized the treatment of various cancers, but has also presented new challenges because of treatment-induced resistance mechanisms in tumors and changes to patients' innate and adaptive immune responses. Several studies have revealed that cancer cells communicate with the immune system dynamically. Dynamic interaction between the tumor and the immune system, and with the cancer-specific therapy, occurs with each immunotherapy. Understanding these interactions will lead to the development of novel combination therapies and innovative sequencing approaches.

In this Special Issue, we welcome articles, reviews, and perspectives regarding clinical and translational cancer immunotherapy, including in vitro and in vivo studies about new immunotherapeutic approaches and tumor-immune cell interactions, acquired immunity resistance to immunotherapy, and immunotherapy biomarkers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI